HLVX 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
公司發布財報數據季度不足，尚無法提供評分
HLVX 近期報酬表現
3.11%
Hillevax inc
2.35%
同產業平均
-0.21%
S&P500
與 HLVX 同產業的標的表現
| 股票代碼 | 公司名稱 | 價值 | 趨勢 | 波段 | 籌碼 | 股利 | 加入追蹤 |
|---|---|---|---|---|---|---|---|
MURA | Mural oncology plc | - | 2 分 | - | - | 1 分 | |
PRME | Prime medicine inc | - | 4 分 | 2 分 | 2 分 | 1 分 | |
NUVL | Nuvalent inc | - | 3 分 | 4 分 | 3 分 | 1 分 | |
NTLA | Intellia therapeutics inc | 5 分 | 3 分 | 4 分 | 3 分 | 1 分 | |
BEAM | Beam therapeutics inc | 3 分 | 3 分 | 2 分 | 3 分 | 1 分 |
- MURA Mural oncology plc價值 -趨勢 2 分波段 -籌碼 -股利 1 分查看更多
HLVX 公司資訊
HilleVax, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing vaccines. The Company's program, HIL-214, is a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. Norovirus is the most common cause of viral AGE worldwide and is characterized by symptoms, including diarrhea, vomiting, abdominal pain, nausea, and, sometimes, fever that may lead to clinically significant dehydration. The Company's HIL-214 is a bivalent (containing two proteins) vaccine candidate consisting of VLPs representing two common genotypes of norovirus and is co-formulated with an aluminum hydroxide (alum) adjuvant, which is commonly used in adult and pediatric vaccines to enhance immunogenicity. HIL-216 includes six common norovirus genotypes, GI.1, GII.2, GII.3, GII.4, GII.6 and GII.17.